Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis (PR Newswire via Yahoo! Finance)
Wyeth Pharmaceuticals, a division of Wyeth , announced today that the U.S. Food and Drug Administration issued an approvable letter on May 21 for bazedoxifene, a selective estrogen receptor modulator, for the treatment of postmenopausal osteoporosis.